Stockscreener 앱 받기
1.69
9.14%
-0.17
시간 외 거래:
1.70
0.01
+0.59%
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics to Participate in Upcoming May Investor Events - The Manila Times
Renaissance Technologies LLC Grows Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.4% in April - Defense World
Was Compass Therapeutics Inc (CMPX)’s session last reading good? - uspostnews.com
JPMorgan Chase & Co. Acquires 227,864 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Inc’s Market Journey: Closing Weak at 1.90, Down -2.06 - DWinneX
Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital - Defense World
Compass Therapeutics (CMPX) Unveils Promising Data at AACR Annua - GuruFocus
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World
It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World
What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com
Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com
Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World
Compass Therapeutics Inc [CMPX] Insider GORDON CARL L sells 3,571,428 Shares – Latest News - knoxdaily.com
Compass Therapeutics begins biliary cancer trial with new drug By Investing.com - Investing.com Canada
Compass Therapeutics begins biliary cancer trial with new drug - Investing.com
Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer - Nasdaq
Compass Therapeutics Announces First Patient Dosed in an - GlobeNewswire
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer - TradingView
Compass Therapeutics Insider Sold Shares Worth $5,678,571, According to a Recent SEC Filing - marketscreener.com
Orbimed advisors sells $5.68 million in Compass Therapeutics shares - Investing.com Australia
Orbimed advisors sells $5.68 million in Compass Therapeutics shares By Investing.com - Investing.com South Africa
Compass Therapeutics director Carl Gordon sells $5.68 million in shares By Investing.com - Investing.com India
Compass Therapeutics director Carl Gordon sells $5.68 million in shares - Investing.com
Compass Therapeutics chief accounting officer acquires $28,400 in stock - Investing.com Australia
Compass Therapeutics chief accounting officer acquires $28,400 in stock By Investing.com - Investing.com India
Compass Therapeutics general counsel buys $30,800 in common stock By Investing.com - Investing.com India
Compass Therapeutics general counsel buys $30,800 in common stock - Investing.com
Compass Therapeutics Executives Increase Holdings - TradingView
Wedbush Research Analysts Lower Earnings Estimates for CMPX - The AM Reporter
HC Wainwright Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World
Leerink Partnrs Has Pessimistic Outlook of CMPX Q2 Earnings - Defense World
FY2028 EPS Estimates for Compass Therapeutics Cut by Wedbush - Defense World
Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform - Defense World
Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint - insights.citeline.com
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs - Defense World
Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital - The AM Reporter
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq
Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN
Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com
Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance
Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 - MarketScreener
Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire
5.24%
자본화:
|
볼륨(24시간):